It is widely reported that healthcare is a top antitrust enforcement priority in the U.S. The healthcare industry has undergone a transformation over the over the last twenty years and now comprises 17.7% of the U.S. gross domestic product and over $3,795.4 billion of the U.S. government budget. Mega-deals among national payors and household names have grabbed headlines and been targets of enforcement by the U.S. Department of Justice, Antitrust Division and Federal Trade Commission. What is less understood is the agencies’ keen interest in private equity and its impact on the healthcare industry — particularly healthcare providers.
PE firms engaging in healthcare transactions should take into account recent enforcement actions and guidance from federal agencies when evaluating possible transactions to minimize risks, The National Law Review recommends. Read more.
